Cardiol Therapeutics Reports Q2 2025 Financial Results with Rising Losses Amid Ongoing Investments in Research and Development.

Cardiol Therapeutics has reported a net loss of $8.35 million for Q2 2025, compared to a loss of $6.59 million in the same period of 2024. The company's cash and cash equivalents decreased from $30.6 million at the end of 2024 to $18.2 million. The financial results reflect ongoing investments in research and development, with operating expenses remaining substantial. Despite promising clinical developments, the company faces substantial financial challenges.

Cardiol Therapeutics Inc. (CRDL) reported a net loss of $8.35 million for the quarter ending June 30, 2025, compared to a loss of $6.59 million in the same period of 2024. The company's cash and cash equivalents decreased from $30.6 million at the end of 2024 to $18.2 million. The financial results reflect ongoing investments in research and development, with operating expenses remaining substantial.

The company's reported earnings per share (EPS) for the quarter was a loss of 10 cents, which was in line with the mean expectation of three analysts for the quarter of 12 cents per share. The reported revenue was zero, matching the analysts' expectations [2].

Despite promising clinical developments, Cardiol Therapeutics faces substantial financial challenges. The company's financial results underscore the need for continued investment in R&D to drive future growth. The company's shares have fallen by 1.5% this quarter and gained 4.7% so far this year.

Analysts have a positive outlook on the company, with the current average analyst rating on the shares being "buy." The breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target for Cardiol Therapeutics Inc. is $9.00, about 85.1% above its last closing price of $1.34 [2].

The company's earnings date for the next quarter is estimated to be Monday, April 7th, 2025, based on last year's report dates [1].

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/CRDL/earnings/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U70ZK:0-cardiol-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/